Physical AI News (Japan)

Physical AI, robotics and compute — reported from Japan.

日本語
· Funding· 日本語で読む

Wuxi Rex Medical Robotics Completes Early-Stage Strategic Financing Worth Tens of Millions of Yuan

Wuxi Rex Medical Robotics completed early-stage strategic financing worth tens of millions of yuan on Nov. 16, 2026. The company plans to use the funds to improve its products and expand globally. Reports did not disclose the exact amount raised or how the funds will be allocated among products.

What happened

Wuxi Rex Medical Robotics announced on Nov. 16, 2026, that it had completed early-stage strategic financing worth tens of millions of yuan. According to Leaderobot, BGI Songhe led the round, and existing shareholder Meian Innovation also made an additional investment. The company plans to use the funds to improve its products and expand globally.

Why it matters

According to Leaderobot, Rex plans to use the funds to improve its products and expand globally. For those involved in developing and commercializing exoskeleton rehabilitation robots, the intended use of the funds offers a point of reference for tracking future product updates and overseas expansion. However, reports do not identify the products involved or the markets targeted.

Analysis

The reported amount was “tens of millions of yuan”; the exact sum and investment terms were not disclosed. This limits the basis for comparing the financing with that of other companies or estimating how much will go to product development. The confirmed plans cover two areas: product improvement and global expansion. The fact that the funds are not earmarked solely for domestic development is the main point of the announcement. However, reports do not specify the products involved, target markets or timing. On the investor lineup, Leaderobot reported that BGI Songhe led the round and Meian Innovation made an additional investment. It also reported that BGI Songhe is backed by BGI Group and Songhe Capital. The article does not establish what technical or business collaboration these organizations will pursue through the investment. Their identities alone do not support an inference of collaboration involving medical data or genetic technologies. Our related coverage includes Bi-Oku Satoru Zou Begins Public Offering in Hong Kong, on Bi-Oku Satoru Zou’s launch of a Hong Kong public offering, and Honmatsu Douryoku Passes Hong Kong Stock Exchange Hearing, on Honmatsu Douryoku passing a hearing at the Hong Kong Stock Exchange. Both articles covered capital-market developments at other companies and do not indicate a relationship with Rex or the company’s future capital plans. The announcement covered here concerns early-stage financing intended for product improvement and overseas expansion, not an IPO process. The headline mentions self-balancing technology, but the excerpted report does not provide information that would allow readers to assess the control method, clinical applications or product performance. Points to watch include the exact size and terms of the financing, which products will be improved, clinical evaluations and the scope of overseas expansion. Until those details are available, the financing alone cannot be used to assess the technology’s clinical efficacy or the company’s commercialization progress.

Sources

Translated from the Japanese original: /news/kaminari-katsu-shi-iryou-suusenman-motono-yuushi-wo-kanryou-2e960d. The Japanese version is authoritative if they differ.